Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated liposomal doxorubicin for induction remission in myelodysplastic syndrome with excess blasts
ChiCTR1800019554Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxorubicin in myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by Army Medical University. Primary endpoint: Rate of complete remission. Started Nov 2018; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on ChiCTR1800019554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019554.